Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02406287 · ClinicalTrials.gov registry record · Phase 1
A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers
A Phase 1 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02406287 is a Phase 1 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 10 participants.
The verdict
NCT02406287, a Phase 1 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
To evaluate the effect of netarsudil (AR-13324) ophthalmic solution on aqueous humor dynamics relative to its placebo.
Interventions
- DRUG Netarsudil (AR-13324) Ophthalmic Solution
- DRUG Netarsudil (AR-13324) Ophthalmic Solution Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02406287
The ClinicalTrials.gov registry entry for NCT02406287 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Netarsudil (AR-13324) Ophthalmic Solution is the first listed.
NCT02406287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02406287 about?
NCT02406287 is a clinical study titled "A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers". To evaluate the effect of netarsudil (AR-13324) ophthalmic solution on aqueous humor dynamics relative to its placebo.
What is the current status of trial NCT02406287?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2015-04. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02406287?
The interventions under investigation include: Netarsudil (AR-13324) Ophthalmic Solution (DRUG), Netarsudil (AR-13324) Ophthalmic Solution Placebo (DRUG).
Who is sponsoring clinical trial NCT02406287?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.